- Report
- January 2024
- 145 Pages
Global
From €4056EUR$4,250USD£3,398GBP
- Report
- November 2023
- 30 Pages
Global
From €2625EUR$2,750USD£2,199GBP
- Report
- January 2022
- 200 Pages
Global
From €7158EUR$7,500USD£5,997GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- April 2023
- 160 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- January 2022
- 111 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- March 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- October 2023
- 698 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Report
- August 2022
United States
From €1851EUR$1,940USD£1,551GBP
- Report
- August 2022
Global
From €1136EUR$1,190USD£952GBP
- Report
- February 2021
Global
From €2825EUR$2,960USD£2,367GBP
- Report
- September 2019
- 75 Pages
Global
From €3102EUR$3,250USD£2,599GBP
- Report
- August 2024
- 94 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- July 2022
- 518 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- January 2025
- 132 Pages
Global
From €907EUR$950USD£760GBP

The Cystic Fibrosis Drug market is a subset of the larger Respiratory Drug market. It is composed of treatments and therapies designed to address the symptoms of cystic fibrosis, a genetic disorder that affects the lungs and digestive system. These drugs are used to reduce the amount of mucus in the lungs, improve breathing, and reduce the risk of infection. They may also be used to treat other symptoms, such as malnutrition, dehydration, and vitamin deficiencies.
The Cystic Fibrosis Drug market is highly competitive, with many companies developing and marketing treatments. Some of the major players in the market include Vertex Pharmaceuticals, Gilead Sciences, Novartis, and GlaxoSmithKline. Other companies, such as AbbVie, Merck, and Pfizer, are also active in the market. Show Less Read more